The SURMOUNT-1 trial (N=2,539), published in the New England Journal of Medicine in 2022 (DOI: 10.1056/NEJMoa2206038), evaluated tirzepatide at 5mg, 10mg, and 15mg weekly doses versus placebo in adults with obesity or overweight
Medical board and malpractice exposure, an honest assessment In a board investigation or malpractice claim, the file you can produce matters more than the evidence base behind the compound
When you run low, the result is often a stubborn, draining sort of tiredness that no amount of coffee seems to fix
Ghrelin (GHRL) is a 28-amino acid cationic peptide hormone that binds to growth hormone secretagogue receptors, releasing neuropeptide Y and Agouti-related peptide (AgRP), subsequently stimulating food intake and decreasing inflammatory cytokine levels
Questions to Ask When consulting about Retatrutide, consider asking about starting doses, expected timeline for results, potential interactions, and monitoring requirements
The committee recommended
